Immunovant (IMVT) Tax Provisions (2018 - 2026)
Immunovant's (IMVT) quarterly Tax Provisions came in at -$2.9 million in Q1 2026, down 590.39% YoY from $583000.0 in Q1 2025, and down 284.21% on a QoQ basis from $1.6 million in Q4 2025.
Immunovant (IMVT) Tax Provisions (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Tax Provisions data on file, last reported at -$2.9 million in Q1 2026.
- Quarterly Tax Provisions fell 590.39% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200000.0 (down 77.53% YoY) and the FY2026 annual result came in at $200000.0, down 77.55% from the prior year.
- Tax Provisions retreated to -$2.9 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $1.6 million in Q4 2025 to a low of -$2.9 million in Q1 2026.
- A 5-year average of $97294.1 and a median of $232000.0 in 2024 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2023 — Tax Provisions tumbled 8158.33% — and 2025, when it soared 1085.71%.
- Tracing IMVT's Tax Provisions over 5 years: stood at $387000.0 in 2022, then tumbled by 127.91% to -$108000.0 in 2023, then soared by 240.74% to $152000.0 in 2024, then jumped by 921.05% to $1.6 million in 2025, then plunged by 284.21% to -$2.9 million in 2026.
- The last three Tax Provisions figures came in at -$2.9 million (Q1 2026), $1.6 million (Q4 2025), and $594000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.86 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 594,000.00 |
| Jun 30, 2025 | 913,000.00 |
| Mar 31, 2025 | 583,000.00 |
| Dec 31, 2024 | 152,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 232,000.00 |
| Dec 31, 2023 | -108,000.00 |
| Sep 30, 2023 | 454,000.00 |
| Jun 30, 2023 | -11,000.00 |
| Mar 31, 2023 | -991,000.00 |
| Dec 31, 2022 | 387,000.00 |
| Sep 30, 2022 | 261,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Mar 31, 2022 | -12,000.00 |
| Sep 30, 2021 | -31,000.00 |
| Jun 30, 2021 | -41,000.00 |
| Mar 31, 2021 | -79,000.00 |